Lenvatinib Success Rate and Survival: — An Honest Look at the Numbers

There is no single response rate because lenvatinib is used in several cancer types, and the published figures differ for each. The proportion of patients who respond in thyroid cancer trials reflects a different population from liver cancer trials or endometrial cancer trials. Ask your oncologist which data applies to your cancer type and what proportion of people in that group responded. That is a question they can answer directly for your situation, and it is a reasonable one to put to them at your next appointment.

It varies considerably between individuals and between cancer types. Trials report median figures — the midpoint of a range — and that range is usually wide. Some people have disease control for substantially longer than the median, and some do not reach it. There is no way to know in advance where you will fall. Ask your oncologist what the median looked like in the trial most relevant to your situation, and understand that your own scan results will tell you more than any published figure.

No. In all trials, a proportion of patients do not respond — meaning the cancer continues to grow despite treatment. This is why your oncologist assessed your tumour's characteristics before recommending lenvatinib, and why regular response assessments are built into the schedule. If lenvatinib is not controlling your disease, your team will tell you at the first response scan and discuss alternatives. Knowing that not everyone responds is not a reason to avoid starting treatment — it is a reason to attend every assessment appointment.

Your team will schedule the first imaging assessment after several weeks of treatment. Some patients notice symptom changes before the scan, but symptoms alone are not a reliable guide — they can improve or worsen for reasons unrelated to the cancer's behaviour. The scan comparison to your baseline is the definitive answer. Ask your oncologist when the first assessment scan is planned and what they will be looking for, so you have a clear timeline rather than waiting without a reference point.

If lenvatinib stops controlling the disease, your oncologist will discuss what comes next. Other systemic treatments, clinical trials, or a different approach to the overall treatment goal may all be options, depending on your cancer type and your general health at that point. Lenvatinib stopping does not mean you have run out of options — it means the plan moves to its next step. Ask your team in advance what the most likely next option would be for your cancer type, so you are not hearing it for the first time at a difficult appointment.

Statistics describe populations, not individuals. A median figure from a published trial tells you where the midpoint of a group fell — it does not predict where you will land. Numbers from general health sites or patient forums may not apply to your cancer type, your stage, or the dose and combination you are on. Use published statistics to understand what a treatment has achieved in a group; use your own scan results to understand what it is achieving for you. If a figure you have read is worrying you, bring it to your oncologist and ask whether it is relevant to your situation.